IL Dong Pharmaceutical

일동제약 · 249420

Health Care Pharmaceuticals · KOSPI

Small-cap

Market cap US$465.4M (₩642.3B)

Overview

IL Dong Pharmaceutical makes prescription medicines, active-vitamin supplements (sold under the Aronamin brand), antibiotics, health supplements, and specialty nutritional foods for patients and consumers in South Korea.

Its products reach end users through the domestic healthcare and retail supply chain. Listed on KOSPI, South Korea's main stock exchange, the company's product range is anchored by its active-vitamin Aronamin line and the antibiotic Flumarin, which together represent its core manufactured goods.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$410.8M
▼ −7.8% YoY
Operating profit · FY2025
US$14.1M
▲ +48.5% YoY
Net income · FY2025
US$17.2M
Turned profitable

Revenue

  • FY2023US$435.3M
  • FY2024US$445.6M
  • FY2025US$410.8M

Operating profit

  • FY2023−US$39.1M
  • FY2024US$9.5M
  • FY2025US$14.1M

Net income

  • FY2023−US$58.7M
  • FY2024−US$9M
  • FY2025US$17.2M

Key ratios (FY2025)

ROE
9.9%
Debt/Eq
139.3%
Op. margin
3.4%
Net margin
4.2%
Rev. YoY
▼ −7.8%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.